{
  "ticker": "EVE",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02958531",
  "id": "02958531",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250616",
  "time": "0838",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250616/pdf/06krwwcb0qdcgh.pdf",
  "summary": "- **Strategic Partnership**: Agreement with TeleDocs Clinic for nationwide prescribing of EVE\u2019s erectile dysfunction oral film (Libbo+) and dysmenorrhea gummy (Dyspro).  \n- **Market Access**: TeleDocs Clinic (first online prescriber) has a network of 3,500+ pharmacies, enhancing product reach.  \n- **Regulatory Timeline**: Libbo+ and Dyspro in final-stage testing; regulatory submissions and manufacturing expected Q3/Q4 2025.  \n- **Agreement Terms**: Two-year prescribing/marketing deal with TeleDocs providing clinical training, digital education, and quarterly reporting.  \n- **Commercial Readiness**: Strengthens EVE\u2019s launch plans for pending regulatory approvals.  \n\n**Material Impact**: Improves commercialization pathway and patient access for high-potential products. Omit if awaiting regulatory clarity.",
  "usage": {
    "prompt_tokens": 1009,
    "completion_tokens": 174,
    "total_tokens": 1183,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-15T22:53:57.814692"
}